Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Annual Report Captures Positive Progress

  • Noxopharm Annual Report released today
  • Positive indications for clinical benefits of proprietary drug candidate Veyonda® continue
  • Key commercialisation milestones met

Sydney, 26 Sept 2019:

Noxopharm (ASX: NOX) is pleased to release its 2019 Annual Report.

This has been an important year for Noxopharm with new trial data continuing to indicate positive clinical benefits of its front-line drug candidate, Veyonda®, in late-stage prostate cancer, pointing to its potential to become an important new drug in both that and other cancers.

For further information please download the attached PDF: Download this document